SPDR S&P Biotech ETF

XBI

Market cap $5.43B

Overview Fund Activity

94.12 USD

-1.58

1.65%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

94.24

+0.12

0.13%

1 day

-1.65%

5 days

-0.91%

1 month

8.28%

3 months

11.57%

6 months

8%

Year to date

2.83%

1 year

-4.99%

5 years

-15.69%

10 years

21.84%

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

18.13% more ownership

Funds ownership: 180.41% [Q1] → 198.54% (+18.13%) [Q2]

5% more capital invested

Capital invested by funds: $9.23B [Q1] → $9.73B (+$506M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 15 [Q1] → 15 (+0) [Q2]

9% less funds holding

Funds holding: 671 [Q1] → 613 (-58) [Q2]

35% less call options, than puts

Call options by funds: $1.47B | Put options by funds: $2.24B

41% less repeat investments, than reductions

Existing positions increased: 159 | Existing positions reduced: 270

47% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 101

See Fund Rankings

Financial journalist opinion

Based on 6 articles about XBI published over the past 30 days

The Motley Fool

As the Fed Pivots, These 3 ETFs Are Positioned to Outperform

The Federal Reserve's inflation battle appears to be ending, and investors who position themselves correctly could capture significant gains. Producer prices unexpectedly dropped in August, while the U.S. government revised past employment figures downward by a staggering 911,000 jobs.

As the Fed Pivots, These 3 ETFs Are Positioned to Outperform

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

Last week, the SPDR S&P Biotech ETF surged 6%.

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from domestic manufacturing to cutting-edge R&D.

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

Schaeffers Research

35 ETFs to Watch After the S&P 500's Most Recent Surge

Over the last 100 trading days, or roughly five months, the S&P 500 Index (SPX) has surged more than 25%.

35 ETFs to Watch After the S&P 500's Most Recent Surge

CNBC Television

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

CNBC Television

Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Power Lunch' to discuss what tariffs mean for the pharma industry, what could be a blockbuster for Eli Lilly and much more.

Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz

Zacks Investment Research

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

XBI: Surprise Exit Of A Tough Regulator At The FDA

XBI has rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a tougher regulatory environment. Vinay Prasad was only appointed in May, but is now leaving the FDA, meaning there will again be a new Director of the Center for Biologics Evaluation and Research. Prasad's appointment caused XBI to drop in May, but the sector still continued on with its recovery.

XBI: Surprise Exit Of A Tough Regulator At The FDA

CNBC Television

Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector

Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.

Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector

Investors Business Daily

Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn

Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month, making good on months of threats.

Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn

See News Rankings

Charts implemented using Lightweight Charts™